IMMUNITYBIO, INC. Increase (Decrease) in Accounts Payable
IMMUNITYBIO, INC. (IBRX) reported Increase (Decrease) in Accounts Payable of -$65.00 thousand for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2019-08-06
- IMMUNITYBIO, INC. increase (decrease) in accounts payable for the quarter ending 2019-06-30 was -$735.00K, a 141.81% decline year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable for the quarter ending 2019-03-31 was $670.00K, a 472.65% increase year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable for the quarter ending 2018-12-31 was -$1.03M.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable for the quarter ending 2018-09-30 was -$1.94M, a 175.82% decline year-over-year.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable for fiscal 2018 was -$1.10M, a 833.33% decline from fiscal 2017.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable for fiscal 2017 was $150.00K, a 83.11% decline from fiscal 2016.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable for fiscal 2016 was $888.00K, a 41.63% increase from fiscal 2015.
- IMMUNITYBIO, INC. increase (decrease) in accounts payable for fiscal 2015 was $627.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$735.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$65.00K 10-Q · filed 2019-08-06 | -$1.10M derived: sum of 3 quarters · filed 2019-08-06 | -$3.04M derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | $670.00K 10-Q · filed 2019-05-08 | -$364.00K derived: sum of 2 quarters · filed 2019-05-08 | -$2.31M derived: sum of 3 quarters · filed 2019-05-08 | -$547.00K derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | -$2.98M derived: sum of 2 quarters · filed 2019-03-13 | -$1.22M derived: sum of 3 quarters · filed 2019-08-06 | -$1.10M 10-K · filed 2019-03-13 |
| 2018-09-30 | -$1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$183.00K derived: sum of 2 quarters · filed 2019-08-06 | -$66.00K 10-Q · filed 2018-11-07 | -$1.41M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.88M 10-Q · filed 2019-08-06 | $532.00K derived: sum of 3 quarters · filed 2019-08-06 | $3.09M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $117.00K 10-Q · filed 2019-05-08 | -$1.23M derived: sum of 2 quarters · filed 2019-05-08 | $1.33M derived: sum of 3 quarters · filed 2019-05-08 | -$458.00K derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | -$1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $1.22M derived: sum of 2 quarters · filed 2019-03-13 | -$575.00K derived: sum of 3 quarters · filed 2019-03-13 | $150.00K 10-K · filed 2019-03-13 |
| 2017-09-30 | $2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $768.00K derived: sum of 2 quarters · filed 2018-11-07 | $1.49M 10-Q · filed 2018-11-07 | $2.06M derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-06-30 | -$1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | -$1.07M 10-Q · filed 2018-08-06 | -$500.00K derived: sum of 3 quarters · filed 2019-03-13 | -$263.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-03-31 | $725.00K 10-Q · filed 2018-05-07 | $1.29M derived: sum of 2 quarters · filed 2019-03-13 | $1.53M derived: sum of 3 quarters · filed 2019-03-13 | $2.35M derived: sum of 4 quarters · filed 2019-03-13 |
| 2016-12-31 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $804.00K derived: sum of 2 quarters · filed 2019-03-13 | $1.63M derived: sum of 3 quarters · filed 2019-03-13 | $888.00K 10-K · filed 2019-03-13 |
| 2016-09-30 | $237.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.06M derived: sum of 2 quarters · filed 2017-11-07 | $321.00K 10-Q · filed 2017-11-07 | -$2.87M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $821.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $84.00K 10-Q · filed 2017-08-07 | -$3.10M derived: sum of 3 quarters · filed 2018-03-12 | -$1.34M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | -$737.00K 10-Q · filed 2017-05-08 | -$3.92M derived: sum of 2 quarters · filed 2018-03-12 | -$2.16M derived: sum of 3 quarters · filed 2018-03-12 | -$209.00K derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | -$3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$1.42M derived: sum of 2 quarters · filed 2018-03-12 | $528.00K derived: sum of 3 quarters · filed 2018-03-12 | $627.00K 10-K · filed 2018-03-12 |
| 2015-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $3.72M derived: sum of 2 quarters · filed 2016-11-10 | $3.81M 10-Q · filed 2016-11-10 | $3.92M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $2.05M 10-Q · filed 2016-08-15 | $2.15M derived: sum of 3 quarters · filed 2017-03-15 | $2.19M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $99.00K 10-Q · filed 2016-05-16 | $201.00K derived: sum of 2 quarters · filed 2017-03-15 | $239.00K derived: sum of 3 quarters · filed 2017-03-15 | |
| 2014-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $140.00K derived: sum of 2 quarters · filed 2017-03-15 | -$347.00K 10-K · filed 2017-03-15 | |
| 2014-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$449.00K 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | -$487.00K 10-Q · filed 2015-09-10 | |||
| 2013-12-31 | $700.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |